14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AQST vs AMPH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AQST carries a Unified Composite Score of 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin), whereas AMPH carries 48.8/100 (HOLD) at $28.25 (10.5x Forward P/E, 18.7% operating margin).
Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. AMPH 48.8/100 HOLD), AMPH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (18.7% vs. -114.1% operating margin) and revenue trajectory (+8.2% vs. -41.0% YoY).
Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5); meanwhile AMPH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.2B market capitalization and 18.7% operating margin.
OpEx & R&D Reinvestment28.1% of Rev ($210M)
90D Engineering Disclosures0 Published
Investor FAQ AQST vs AMPH Key Questions & Quantitative Answers
As of Nov 20, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AQST carries a Unified Composite Score of 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin), whereas AMPH carries 48.8/100 (HOLD) at $28.25 (10.5x Forward P/E, 18.7% operating margin). Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. AMPH 48.8/100 HOLD), AMPH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (18.7% vs. -114.1% operating margin) and revenue trajectory (+8.2% vs. -41.0% YoY). Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5); meanwhile AMPH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AMPH leads the Growth & Scale pillar: AQST posts -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin), compared with AMPH at +8.2% YoY revenue growth and +135.1% YoY earnings growth on $746M TTM revenue (46.8% gross margin, 18.7% operating margin). Across the 5-period historical trajectory (Q3 '25 to Q3 '26), AQST cumulative revenue shifted -40.0% while AMPH shifted +7.8%. In operating R&D and SG&A reinvestment, AQST deploys N/A (0 90-day corporate R&D disclosures) versus 28.1% of Rev ($210M) (0 disclosures) for AMPH.
AMPH screens cheaper on headline valuation multiples. AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin), whereas AMPH trades at 10.5x Forward P/E, 12.9x Trailing P/E, 2.77x PEG, and 2.3x EV/Revenue (6.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AQST (0.0% ROE) versus AMPH (12.4% ROE) capital efficiency.
In options market volatility and institutional positioning, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk). By comparison, AMPH carries 460.7% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.07β · 37% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.